• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

87
51
37
36
26

COUNTRY

14
14
13
12
11

CATEGORIES

  • 189
  • 110
  • 68
  • 19
  • 17
  • 13
  • 13
  • 9
  • 8
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
SHOW ALL…

PRICE

74
90
225
371

PUBLISHED

4
46
99
371

PRODUCT TYPE

286
85

Search "Eli Lilly and Company - SWOT Analysis" returned 371 results.

PRODUCT TITLE
Eli Lilly and Company - SWOT Framework Analysis Eli Lilly and Company - SWOT Framework Analysis - Product Thumbnail Image

Eli Lilly and Company - SWOT Framework Analysis

SWOT Analysis, is a strategic planning tool used to evaluate the Strengths, Weaknesses, Opportunities, and Threats involved in a project or in a business venture. It involves specifying the objective...

April 2013
FROM
Eli Lilly & Co. Company Profile - Business Description, Strategies, SWOT and Financial Analysis Eli Lilly & Co. Company Profile - Business Description, Strategies, SWOT and Financial Analysis - Product Thumbnail Image

Eli Lilly & Co. Company Profile - Business Description, Strategies, SWOT and Financial Analysis

“Eli Lilly & Co. Company Profile” is a comprehensive report on Eli Lilly & Co.. The report provides complete information on the operations, organization structure and financial information details of...

October 2013
FROM

Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review

Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled...

May 2014
FROM

Eli Lilly and Company Market Share Analysis

Eli Lilly and Company Market Share Analysis Summary Our new report, “Eli Lilly and Company Market Share Analysis” provides in-depth information on Eli Lilly and Company's market position in the different...

September 2012
FROM

Eli Lilly and Company - SWOT, Strategy and Corporate Finance Report

Eli Lilly and Company - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product...

January 2013
FROM

Eli Lilly and Company - Strategy and SWOT Report

Eli Lilly and Company - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service...

May 2014
FROM
Analysis of Eli Lilly and Company Analysis of Eli Lilly and Company - Product Thumbnail Image

Analysis of Eli Lilly and Company

Analysis of Eli Lilly and Company. A complete and comprehensive analysis of Eli Lilly and Company, includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry,...

January 2013
FROM

Psoriasis - Current and Future Players

Psoriasis - Current and Future Players Summary GlobalData has released its pharma report, “Psoriasis - Current and Future Players”. The report is a vital source of up-to-date information with in-depth...

May 2013
FROM
Product Profiles: Non-Insulin Antidiabetics - Options abound as the SGLT-2 class prepares for market entry Product Profiles: Non-Insulin Antidiabetics - Options abound as the SGLT-2 class prepares for market entry - Product Thumbnail Image

Product Profiles: Non-Insulin Antidiabetics - Options abound as the SGLT-2 class prepares for market entry

The 2012–21 forecast period will see the loss of exclusivity for the leading non-insulin antidiabetic Actos franchise, while new launches include the first once-weekly GLP-1 agonists and the oral SGLT-2...

August 2012
FROM
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis Lung Cancer Therapeutics Market Outlook and Pipeline Analysis - Product Thumbnail Image

Lung Cancer Therapeutics Market Outlook and Pipeline Analysis

With over 50% of all non-small cell lung cancer (NSCLC) patients diagnosed at the advanced stages of the disease, and 95% of all small-cell lung cancer (SCLC) patients unsuitable for surgical resection,...

November 2009
FROM
Circulating Tumor Cells (Ctcs) And Cancer Stem Cells (Cscs) Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018 Circulating Tumor Cells (Ctcs) And Cancer Stem Cells (Cscs) Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018 - Product Thumbnail Image

Circulating Tumor Cells (Ctcs) And Cancer Stem Cells (Cscs) Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018

Circulating tumor cell technology is an enabling technology for recovery and analysis of separated cancer cells in the peripheral blood CTC technology offers advantages like high sensitivity, high specificity,...

August 2012
FROM

PharmaPoint: Rheumatoid Arthritis - Current and Future Players

PharmaPoint: Rheumatoid Arthritis - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Rheumatoid Arthritis - Current and Future Players”. The report is a...

November 2012
FROM
Mexico Pharmaceutical Market Analysis, 2010-2014 Mexico Pharmaceutical Market Analysis, 2010-2014 - Product Thumbnail Image

Mexico Pharmaceutical Market Analysis, 2010-2014

Having displayed fluctuating growth rates in the years 2005-2009 the Mexico pharmaceuticals market is expected to stabilize in 2010 follow by the unchanged growth rates over the years up to 2014. The...

August 2010
FROM
Company Analysis - Merck & Co., Inc. Company Analysis - Merck & Co., Inc. - Product Thumbnail Image

Company Analysis - Merck & Co., Inc.

Company Analysis assists individual investors, managers and companies in evaluating opportunities, trends, market innovations as well as in selecting appropriate information solutions in order to make...

January 2012
FROM
Product Profiles: Osteoporosis - Novel candidates offer the greatest potential Product Profiles: Osteoporosis - Novel candidates offer the greatest potential - Product Thumbnail Image

Product Profiles: Osteoporosis - Novel candidates offer the greatest potential

Despite major brands losing market exclusivity increasing cost competition, the osteoporosis market remains attractive. Leading osteoporosis companies continue to promote their products and develop...

November 2011
FROM
Product Profiles: Non-Small Cell Lung Cancer Product Profiles: Non-Small Cell Lung Cancer - Product Thumbnail Image

Product Profiles: Non-Small Cell Lung Cancer

This report analyses key marketed and pipeline drugs for non-small cell lung cancer, including assessment of current and future market strength of approved drugs, drug development strategies, and commercial...

April 2012
FROM

Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

GBI Research, the leading business intelligence provider, has released its latest research “Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of...

January 2012
FROM

Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives

GBI Research, the leading business intelligence provider, has released its latest research, “Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs)...

October 2012
FROM
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers - Product Thumbnail Image

Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers

Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy The non-insulins antidiabetics market is forecast to grow to $18 8 billion...

December 2010
FROM
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy. Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy. - Product Thumbnail Image

Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.

Introduction Datamonitor forecasts the non-insulins antidiabetics market to grow to $18.8 billion in 2019 for the seven major markets, with pipeline products contributing 39% of sales. GLP-1 agonists...

December 2010
FROM
Loading Indicator